<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02265965</url>
  </required_header>
  <id_info>
    <org_study_id>UCSF-OB-NTG</org_study_id>
    <nct_id>NCT02265965</nct_id>
  </id_info>
  <brief_title>Trial of IV NTG for CD After Second Stage Arrest for the Prevention of Uterine Extension</brief_title>
  <acronym>NITRO</acronym>
  <official_title>Randomized Controlled Trial of IV Nitroglycerin in Cesarean Deliveries After Second Stage Arrest for the Prevention of Uterine Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled clinical trial of IV nitroglycerin at cesarean delivery for second
      stage arrest of descent to prevent or uterine extension at the hysterectomy site.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravenous nitroglycerin resulting in uterine relaxation has been standardly utilized for
      various obstetrics conditions, e.g. breech extraction of second twin in vaginal deliveries,
      uterine relaxation after tachysystole in labor, prior to external cephalic version, and
      during difficult fetal extraction during cesarean delivery for arrest of descent in labor.
      Currently the use of nitroglycerin is at equipoise in obstetrics for difficult cesarean
      delivery after second stage arrest in labor. The clinical trial will randomize women who
      undergo cesarean delivery for second stage arrest in labor to receive IV nitroglycerin vs
      saline at the time of hysterotomy. The primary outcomes will be maternal: uterine extension,
      blood loss, total fetal extraction time, surgical time; neonatal: cord gases at delivery,
      apgar scores, admission to neonatal intensive care unit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">July 1, 2018</completion_date>
  <primary_completion_date type="Actual">July 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Uterine Extension of Hysterotomy</measure>
    <time_frame>During cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest</time_frame>
    <description>Obstetrician determined whether the subject had an uterine extension.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Umbilical Artery Blood pH</measure>
    <time_frame>At time of cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest</time_frame>
    <description>Measure of umbilical artery blood pH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Deliveries After Which Neonate is Admitted to NICU</measure>
    <time_frame>After cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Deliveries in Which Cord Blood Base Deficit is More Negative Than or Equal to Negative 12</measure>
    <time_frame>At time of cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest</time_frame>
    <description>A cord blood base deficit more negative than negative 12 is abnormal and a sign of metabolic acidosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>APGAR at 5 Minutes</measure>
    <time_frame>Immediately after cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest</time_frame>
    <description>The APGAR scale is determined by evaluating the newborn baby on five simple criteria -- Appearance, Pulse, Grimace, Activity, Respiration -- on a scale from zero to two, then summing up the five values thus obtained. The resulting APGAR score ranges from zero to 10. Zero is the worst possible score and 10 is the highest possible score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fetal Extraction Time in Seconds</measure>
    <time_frame>At time of cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest</time_frame>
    <description>Time from uterine incision to delivery (body of neonate fully extracted from uterus)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Operative Time in Minutes</measure>
    <time_frame>After cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest</time_frame>
    <description>Time from uterine incision to out of room</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Blood Loss</measure>
    <time_frame>During and after cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest</time_frame>
    <description>Total blood loss will be measured</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Prolonged Second Stage of Labor</condition>
  <arm_group>
    <arm_group_label>Intravenous Nitroglycerin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Saline</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous nitroglycerin</intervention_name>
    <description>Infusion at started at time of hysterotomy and stopped at neonate delivery</description>
    <arm_group_label>Intravenous Nitroglycerin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: women 37weeks or greater gestation diagnosed with second stage arrest
        of descent undergoing cesarean delivery -

        Exclusion Criteria: elective, active phase arrest cesarean delivery, successful operative
        vaginal delivery

        -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer M Lucero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University California San Francisco-Labor and Delivery</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Isquick S, Henry D, Nakagawa S, Moghadassi M, Thiet MP, Norton M, Lucero J. The association between nitroglycerin use and adverse outcomes in women undergoing cesarean delivery in the second stage of labor. J Matern Fetal Neonatal Med. 2017 Jun;30(11):1297-1301. doi: 10.1080/14767058.2016.1212010. Epub 2016 Aug 2.</citation>
    <PMID>27405400</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 22, 2014</study_first_submitted>
  <study_first_submitted_qc>October 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2014</study_first_posted>
  <results_first_submitted>April 14, 2020</results_first_submitted>
  <results_first_submitted_qc>May 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2020</results_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02265965/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intravenous Nitroglycerin</title>
          <description>Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
intravenous nitroglycerin: Infusion at started at time of hysterotomy and stopped at neonate delivery</description>
        </group>
        <group group_id="P2">
          <title>Intravenous Saline</title>
          <description>Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intravenous Nitroglycerin</title>
          <description>Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
intravenous nitroglycerin: Infusion at started at time of hysterotomy and stopped at neonate delivery</description>
        </group>
        <group group_id="B2">
          <title>Intravenous Saline</title>
          <description>Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.4" spread="4.1"/>
                    <measurement group_id="B2" value="34.3" spread="3.3"/>
                    <measurement group_id="B3" value="34.7" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi-racial or other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maternal body mass index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.4" spread="3.9"/>
                    <measurement group_id="B2" value="25.3" spread="4.2"/>
                    <measurement group_id="B3" value="24.2" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Uterine Extension of Hysterotomy</title>
        <description>Obstetrician determined whether the subject had an uterine extension.</description>
        <time_frame>During cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Nitroglycerin</title>
            <description>Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
intravenous nitroglycerin: Infusion at started at time of hysterotomy and stopped at neonate delivery</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Saline</title>
            <description>Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Uterine Extension of Hysterotomy</title>
          <description>Obstetrician determined whether the subject had an uterine extension.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Umbilical Artery Blood pH</title>
        <description>Measure of umbilical artery blood pH</description>
        <time_frame>At time of cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Nitroglycerin</title>
            <description>Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
intravenous nitroglycerin: Infusion at started at time of hysterotomy and stopped at neonate delivery</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Saline</title>
            <description>Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered</description>
          </group>
        </group_list>
        <measure>
          <title>Umbilical Artery Blood pH</title>
          <description>Measure of umbilical artery blood pH</description>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="0"/>
                    <measurement group_id="O2" value="7.3" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Deliveries After Which Neonate is Admitted to NICU</title>
        <time_frame>After cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Nitroglycerin</title>
            <description>Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
intravenous nitroglycerin: Infusion at started at time of hysterotomy and stopped at neonate delivery</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Saline</title>
            <description>Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Deliveries After Which Neonate is Admitted to NICU</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Deliveries in Which Cord Blood Base Deficit is More Negative Than or Equal to Negative 12</title>
        <description>A cord blood base deficit more negative than negative 12 is abnormal and a sign of metabolic acidosis.</description>
        <time_frame>At time of cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Nitroglycerin</title>
            <description>Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
intravenous nitroglycerin: Infusion at started at time of hysterotomy and stopped at neonate delivery</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Saline</title>
            <description>Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Deliveries in Which Cord Blood Base Deficit is More Negative Than or Equal to Negative 12</title>
          <description>A cord blood base deficit more negative than negative 12 is abnormal and a sign of metabolic acidosis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>APGAR at 5 Minutes</title>
        <description>The APGAR scale is determined by evaluating the newborn baby on five simple criteria -- Appearance, Pulse, Grimace, Activity, Respiration -- on a scale from zero to two, then summing up the five values thus obtained. The resulting APGAR score ranges from zero to 10. Zero is the worst possible score and 10 is the highest possible score.</description>
        <time_frame>Immediately after cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Nitroglycerin</title>
            <description>Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
intravenous nitroglycerin: Infusion at started at time of hysterotomy and stopped at neonate delivery</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Saline</title>
            <description>Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered</description>
          </group>
        </group_list>
        <measure>
          <title>APGAR at 5 Minutes</title>
          <description>The APGAR scale is determined by evaluating the newborn baby on five simple criteria -- Appearance, Pulse, Grimace, Activity, Respiration -- on a scale from zero to two, then summing up the five values thus obtained. The resulting APGAR score ranges from zero to 10. Zero is the worst possible score and 10 is the highest possible score.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="9" upper_limit="9"/>
                    <measurement group_id="O2" value="9" lower_limit="8" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fetal Extraction Time in Seconds</title>
        <description>Time from uterine incision to delivery (body of neonate fully extracted from uterus)</description>
        <time_frame>At time of cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Nitroglycerin</title>
            <description>Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
intravenous nitroglycerin: Infusion at started at time of hysterotomy and stopped at neonate delivery</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Saline</title>
            <description>Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered</description>
          </group>
        </group_list>
        <measure>
          <title>Fetal Extraction Time in Seconds</title>
          <description>Time from uterine incision to delivery (body of neonate fully extracted from uterus)</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.9" spread="33.1"/>
                    <measurement group_id="O2" value="131" spread="84.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Operative Time in Minutes</title>
        <description>Time from uterine incision to out of room</description>
        <time_frame>After cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Nitroglycerin</title>
            <description>Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
intravenous nitroglycerin: Infusion at started at time of hysterotomy and stopped at neonate delivery</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Saline</title>
            <description>Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered</description>
          </group>
        </group_list>
        <measure>
          <title>Total Operative Time in Minutes</title>
          <description>Time from uterine incision to out of room</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.3" spread="22.0"/>
                    <measurement group_id="O2" value="74.2" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgical Blood Loss</title>
        <description>Total blood loss will be measured</description>
        <time_frame>During and after cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Nitroglycerin</title>
            <description>Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
intravenous nitroglycerin: Infusion at started at time of hysterotomy and stopped at neonate delivery</description>
          </group>
          <group group_id="O2">
            <title>Intravenous Saline</title>
            <description>Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered</description>
          </group>
        </group_list>
        <measure>
          <title>Surgical Blood Loss</title>
          <description>Total blood loss will be measured</description>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="935.7" spread="217.4"/>
                    <measurement group_id="O2" value="1036.4" spread="201.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were evaluated at 6 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intravenous Nitroglycerin</title>
          <description>Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
intravenous nitroglycerin: Infusion at started at time of hysterotomy and stopped at neonate delivery</description>
        </group>
        <group group_id="E2">
          <title>Intravenous Saline</title>
          <description>Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Lucero, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415-476-5535</phone>
      <email>jennifer.lucero@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

